These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17062205)

  • 1. Intracoronary infusion of levosimendan to treat postpericardiotomy heart failure.
    Caimmi PP; Grossini E; Molinari C; Vacca G; Teodori G
    Ann Thorac Surg; 2006 Nov; 82(5):e33-4. PubMed ID: 17062205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of acute cardiac failure by intracoronary administration of levosimendan.
    Caimmi PP; Kapetanakis EI; Beggino C; Molinari C; Giustini G; Crosio E; Reposo G; Micalizzi E; Vacca G; Grossini E
    J Cardiovasc Pharmacol; 2011 Sep; 58(3):246-53. PubMed ID: 21654504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial.
    Lahtinen P; Pitkänen O; Pölönen P; Turpeinen A; Kiviniemi V; Uusaro A
    Crit Care Med; 2011 Oct; 39(10):2263-70. PubMed ID: 21666445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake.
    Michaels AD; McKeown B; Kostal M; Vakharia KT; Jordan MV; Gerber IL; Foster E; Chatterjee K
    Circulation; 2005 Mar; 111(12):1504-9. PubMed ID: 15781741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: alteration of force-frequency and relaxation-frequency relationships.
    Givertz MM; Andreou C; Conrad CH; Colucci WS
    Circulation; 2007 Mar; 115(10):1218-24. PubMed ID: 17339544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience.
    Parle NM; Thomas MD; Dembo L; Best M; Driscoll GO
    Heart Lung Circ; 2008 Jun; 17(3):206-10. PubMed ID: 18242130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the clinical, hemodynamic and neurohormonal response to levosimendan administration in decompensated heart failure patients. One-month follow-up.
    Sargento L; Brito D; Matias JS; Madeira H
    Rev Port Cardiol; 2007; 26(7-8):717-26. PubMed ID: 17939581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levosimendan: a new dual-action drug in the treatment of acute heart failure.
    Mebazaa A; Erhardt L
    Int J Clin Pract; 2003 Jun; 57(5):410-6. PubMed ID: 12846347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levosimendan for weaning from cardiopulmonary bypass after coronary artery bypass grafting.
    Akgul A; Mavioglu L; Katircioglu SF; Pac M; Cobanoglu A
    Heart Lung Circ; 2006 Oct; 15(5):320-4. PubMed ID: 16860605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levosimendan vs. intra-aortic balloon pump in high-risk cardiac surgery.
    Lomivorotov VV; Cherniavskiy AM; Boboshko VA; Kornilov IA; Lomivorotov VN; Karaskov AM
    Asian Cardiovasc Thorac Ann; 2011 Apr; 19(2):154-9. PubMed ID: 21471262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan.
    Antila S; Kivikko M; Lehtonen L; Eha J; Heikkilä A; Pohjanjousi P; Pentikäinen PJ
    Br J Clin Pharmacol; 2004 Apr; 57(4):412-5. PubMed ID: 15025738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levosimendan produces an additional clinical and hemodynamic benefit in patients with decompensated heart failure successfully submitted to a fluid removal treatment.
    Giglioli C; Cecchi E; Landi D; Chiostri M; Spini V; Valente S; Gensini GF; Romano SM
    Congest Heart Fail; 2012; 18(1):47-53. PubMed ID: 22277178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic-pharmacodynamic interrelationships of intravenous and oral levosimendan in patients with severe congestive heart failure.
    Põder P; Eha J; Sundberg S; Antila S; Heinpalu M; Loogna I; Planken U; Rantanen S; Lehtonen L
    Int J Clin Pharmacol Ther; 2003 Aug; 41(8):365-73. PubMed ID: 12940594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone.
    Nanas JN; Papazoglou PP; Terrovitis JV; Kanakakis J; Dalianis A; Tsolakis E; Tsagalou EP; Agrios N; Christodoulou K; Anastasiou-Nana MI
    Am J Cardiol; 2004 Nov; 94(10):1329-32. PubMed ID: 15541261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of levosimendan in patients with chronic heart failure: Does rhythm matter?
    Yontar OC; Yilmaz MB; Yalta K; Tandoğan I
    Anadolu Kardiyol Derg; 2010 Aug; 10(4):310-6. PubMed ID: 20693125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripartum cardiomyopathy: a new successful setting for levosimendan.
    Benezet-Mazuecos J; de la Hera J
    Int J Cardiol; 2008 Jan; 123(3):346-7. PubMed ID: 17324479
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure.
    Parissis JT; Adamopoulos S; Antoniades C; Kostakis G; Rigas A; Kyrzopoulos S; Iliodromitis E; Kremastinos D
    Am J Cardiol; 2004 May; 93(10):1309-12. PubMed ID: 15135713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone.
    Nanas JN; Papazoglou P; Tsagalou EP; Ntalianis A; Tsolakis E; Terrovitis JV; Kanakakis J; Nanas SN; Alexopoulos GP; Anastasiou-Nana MI
    Am J Cardiol; 2005 Mar; 95(6):768-71. PubMed ID: 15757608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of programmed forms of cell death by intracoronary levosimendan during regional myocardial ischemia in anesthetized pigs.
    Grossini E; Caimmi PP; Platini F; Molinari C; Uberti F; Cattaneo M; Valente G; Mary DA; Vacca G; Tessitore L
    Cardiovasc Drugs Ther; 2010 Feb; 24(1):5-15. PubMed ID: 20162343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure.
    Lilleberg J; Laine M; Palkama T; Kivikko M; Pohjanjousi P; Kupari M
    Eur J Heart Fail; 2007 Jan; 9(1):75-82. PubMed ID: 16829185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.